Mexican clinic uses Ibogaine for addiction treatment with Trump backing
Sky News reports from a Mexican clinic that uses Ibogaine to treat addiction, with support from the Trump administration.
The Full Story
A plain summary built from the channels that reported this story.
A clinic in Baja California, Mexico, is using the powerful psychedelic drug Ibogaine to treat addiction and trauma, with patients travelling from the United States where the substance remains illegal. The treatment has gained political attention after President Donald Trump signed an executive order to fast-track clinical research into psychedelics, including Ibogaine.
Ibogaine, derived from a West African shrub, is unregulated and carries significant risks. Doctors at the clinic carefully calculate doses because the drug can cause fatal cardiac arrest if given incorrectly or to patients with underlying heart conditions. Patients are monitored throughout the experience, which involves music and lights to guide the psychedelic trip.
One patient, Ruby, a recovering addict with a history of PTSD, took a test dose before the full treatment. The next day she reported a reduction in her constant anxiety, saying she no longer felt her heart pounding in her chest. Other patients, like Steve and Kyle, are trying to kick drug addiction. Steve was detoxing from fentanyl before taking Ibogaine, and said the risk was worth it because he already does dangerous drugs.
Advocates believe Ibogaine can reset the brain and cure addiction and deep trauma. However, scientists warn that the push to fast-track the drug is premature. Without long-term clinical trials, the safety and efficacy of Ibogaine remain unknown. One researcher noted that in an unregulated black market of treatment in clandestine locations, there is no reliable data on whether the drug is safe.
The Trump administration's support for psychedelic research has surprised many, given the conservative anti-drug stance of past Republican figures. The executive order aims to speed up Ibogaine research and approval, but critics argue the move is too hasty and could put patients at risk.
On screen
Stills are sampled automatically at 60-second intervals. Where shown, the still is the nearest available frame from the relevant broadcast segment and is included to show what was on screen during that part of the broadcast. A still may not correspond to the exact second of a quoted phrase.
Key Claims
Claims reported during this story's coverage, mapped by channel. Ordered by how many channels carried each claim.
| Claim | Sky News |
|---|---|
| Ibogaine can cause fatal cardiac arrest if the dose is too high or the patient has existing heart problems. | |
| Patients come mainly from the United States where Ibogaine is illegal. | |
| President Trump signed an executive order to fast-track Ibogaine research and approval. |
Channel Perspectives
What each channel focused on, with key quotes.
Sky News focused on the human story of patients undergoing Ibogaine treatment, balancing the potential benefits with the serious risks. The report highlighted the political context of Trump's executive order and the concerns of scientists who say the fast-tracking is premature. The tone was investigative and neutral, giving voice to both advocates and critics.
- “Ibogaine is so potent it can cause fatal cardiac arrest if the dose is too high or the patient has existing heart problems.”
- “Testimonies like Ruby's are helping to further the case for Ibogaine with politicians.”
- “But with no long-term clinical trials into Ibogaine, the concern is that President Trump is moving too quickly to fast-track it in the United States.”
Broadcast Timeline
News broadcasts tracked for this story, in time order.